What's Happening?
Researchers at Westlake University in China, led by Bobo Dang, PhD, and Ting Zhou, PhD, have developed a high-throughput platform for engineering fast-acting covalent protein therapeutics. This platform addresses the kinetic mismatch in covalent protein drugs
by enabling rapid covalent bond formation, which is crucial for effective cancer and antiviral therapies. The platform combines yeast surface display with chemoselective protein modification, allowing for the screening of diverse crosslinkers and millions of protein variants. The researchers successfully developed a covalent antagonist targeting PD-L1, named IB101, which demonstrated strong antitumor activity in mouse models. Additionally, a covalent IL-18 variant, IB201, was engineered to enhance signaling strength and duration, showing potent antitumor immune responses without systemic toxicity. The platform's versatility was further demonstrated by developing a covalent inhibitor targeting the receptor-binding domain of SARS-CoV-2, showing durable viral neutralization.
Why It's Important?
The development of this high-throughput platform represents a significant advancement in the field of biologics, particularly for cancer immunotherapy and antiviral treatments. By overcoming the limitations of slow covalent bond formation, this platform enables the creation of protein therapeutics with rapid kinetics and sustained target engagement. This could lead to more effective treatments for cancer and viral infections, potentially improving patient outcomes and expanding therapeutic options. The ability to engineer fast-acting covalent protein therapeutics could also reduce treatment times and improve the safety profile of these drugs, making them more accessible and appealing to healthcare providers and patients.
